-
A
Gene signatures indicating the Golgi‐associated vesicle biogenesis‐ and membrane trafficking‐related genes are significantly enriched in USP8‐high (n = 38) patients versus USP8‐low (n = 39) expressing patients; shown by preranked gene‐set enrichment analysis (GSEA).
-
B
Heatmap shows the upregulated genes upon USP8 overexpression and the downregulated genes upon USP8 depletion when compared with control MDA‐MB‐231 cells by RNA‐seq analysis (left panel). qRT–PCR analysis of control or MDA‐MB‐231 cells stably overexpressing USP8 (USP8 OE) or USP8 shRNA (right panel).
-
C
Go enrichment analysis of significantly altered gene sets in USP8 overexpressed MDA‐MB‐231 cells versus control.
-
D
Go enrichment analysis of significant up‐ and downregulated gene sets in control versus USP8‐depleted MDA‐MB‐231 cells.
-
E
FACS analysis of EVs from 4T1 and MDA‐MB‐231 cells infected with lentivirus encoding control shRNA (Co.sh) or USP8 shRNA.
-
F
Immunoblot analysis of EVs from MDA‐MB‐231 cells infected with lentivirus encoding control shRNA (Co.sh) or USP8 shRNA (#1 & #2).
-
G
Immunoblot analysis of the EVs derived from MDA‐MB‐231 cells ectopically expressing USP8 wt/cs.
-
H
Experimental procedure in vivo: BALB/c mice were nipple injected with 4T1‐Luc cells (5 × 105 cells per mouse) expressing control shRNA or doxycycline‐inducible shRNA‐targeting USP8 (shUSP8), and tumors were grown for 3 weeks, followed by the administration of doxycycline for 3 weeks (n = 6 for each group).
-
I
Quantification of the percentage of TβRII+ crEVs in plasma samples from mice at day 24.
-
J
Immunoblot analysis of tumor and the TEVs (left panel) and quantification of the percentage of TβRII+ EVs (right panel) in plasma samples from mice at day 42.
-
K
Normalized photon flux at the indicated times.
-
L
Representative BLI signals of the primary tumor in each group at day 42 after implantation of 4T1 cells (2 × 105 cells per mouse, n = 6 per group).
-
M
Normalized BLI signals (left panel) and bioluminescent images (right panel) of the lung metastasis nodules. Scale bars, 2 mm.
-
N
Percentage of CD8+ T cells of tumor‐draining lymph nodes (TDLN) at day 42.